Glenmark Pharmaceuticals Limited (GLENMARK.BO)

1,230.65 +9.50 (+0.78%) At close: 03:29PM IST

Glenmark Pharmaceuticals Limited

Glenmark House
B.D. Sawant Marg Chakala, Off Western Express Highway Andheri (East)
Mumbai 400099
India
91 22 4018 9999
https://www.glenmarkpharma.com

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full Time Employees: 

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Glenn Mario Saldanha	Chairman, MD & CEO	161.85M	N/A	1970
Mr. V. S. Mani	Global CFO & Executive Director	102.47M	N/A	1965
Ms. Cherylann Maria Pinto	Executive Director of Corporate Services & Executive Director	45.86M	N/A	1967
Mr. Harish Vinayak Kuber	Company Secretary & Compliance Officer	N/A	N/A	N/A
Mr. Alind Sharma	President and Chief Human Resources Officer	N/A	N/A	1971
Mr. Sanjeev Krishan	President and Business Head of North America	N/A	N/A	N/A
Mr. Ulhas R. Dhuppad	President & Head of Global Pharmaceutical Development	N/A	N/A	1967
Mr. Indrajit Bose	President & Chief Quality Officer	N/A	N/A	N/A
Mr. Brijlal Motwani	President & Global Head of Formulation Operations	N/A	N/A	N/A
Mr. Alok Malik	President & Business Head of India Formulations	N/A	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in INR.

Description

Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and markets pharmaceutical products in India, North America, Latin America, Europe, Japan, and internationally. The company provides branded and generic formulations in the therapeutic areas of dermatology, respiratory, and oncology; and various active pharmaceutical ingredients. Its product pipeline includes ISB 2001, a BCMA x CD38 x CD3 trispecific antibody, which is in Phase 1 clinical trial for oncology; GRC 39815, a retinoid-related orphan receptor gamma t inverse agonist, which is in Phase 1 clinical trial for the treatment of chronic obstructive pulmonary disease; and GRC 54276, a hematopoietic progenitor kinase 1 inhibitor, which is in Phase 1 clinical trial for the treatment of solid tumors. Its pipeline also comprises ISB 1342, CD38 X CD3 bispecific antibody, which is in Phase 1 clinical trial for the treatment of relapsed/refractory multiple myeloma; ISB 1442, a CD38 x CD47 immune cell engager, which is in Phase 1 clinical trial for the treatment of relapsed/refractory multiple myeloma; ISB 880, a IL-1RAP antibody, which is in Phase 1 clinical trial for the treatment of autoimmune diseases; and ISB 830, a OX40 antagonist, which is in Phase 2 clinical trial for the treatment of atopic dermatitis. In addition, the company offers Ryaltris nasal spray for the treatment of seasonal allergic rhinitis. Glenmark Pharmaceuticals Limited was incorporated in 1977 and is based in Mumbai, India.

Corporate Governance

Glenmark Pharmaceuticals Limited’s ISS Governance QualityScore as of June 1, 2024 is 8. The pillar scores are Audit: 6; Board: 7; Shareholder Rights: 1; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.